{"gene":"MS4A6A","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":2022,"finding":"MS4A6A promotes surface expression of FcεRI complexes on human mast cells and facilitates IgE-mediated degranulation, functioning as a compensatory FcεRIβ-like protein that traffics the FcεRI receptor complex to the cell surface.","method":"Exon-skipping oligonucleotides targeting FcεRIβ combined with functional degranulation assays in human mast cells; loss-of-function and compensation experiments","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 — clean loss-of-function with defined cellular phenotype (degranulation), mechanistic link to FcεRI trafficking established, single lab","pmids":["36424895"],"is_preprint":false},{"year":2025,"finding":"MS4A6A forms a complex with and blocks the co-receptor DAP12, which modulates the levels, cell surface localization, and signaling of TREM2 and other receptors. MS4A4A interacts with MS4A6A and protects it from degradation, thereby indirectly restraining TREM2 signaling.","method":"Co-immunoprecipitation, CRISPR knockout, MS4A4A-degrading antibodies in primary human microglia, non-human primates, and amyloid mouse model; western blot for TREM2 protein levels","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal Co-IP for complex identification, CRISPR KO, antibody-mediated degradation, and multiple orthogonal model systems (human cells, NHP, mouse); replicated across preprint and peer-reviewed publication","pmids":["41435829"],"is_preprint":false},{"year":2025,"finding":"MS4A6A deficiency (Ms4a6d knockout in APP/PS1 mice) impairs microglial phagocytosis and envelopment of amyloid plaques, leading to increased plaque burden, less compact plaque structure, and more severe synaptic damage; mechanistically, Ms4a6d deficiency disinhibits NF-κB signaling, exacerbating inflammation in microglia and astrocytes.","method":"Ms4a6d-deficient APP/PS1 mouse model, high-resolution microscopy, biochemistry, behavioral analysis, immunostaining; overexpression in human microglia cell line with transcriptomic readout","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and molecular phenotypes (phagocytosis, NF-κB pathway), orthogonal overexpression experiment, in vivo model","pmids":["40877951"],"is_preprint":false},{"year":2025,"finding":"MS4A6A promotes endothelial dysfunction and monocyte adhesion in ox-LDL-stimulated human umbilical vein endothelial cells by activating the IKK/NF-κB signaling pathway; silencing MS4A6A reduced inflammatory cytokines, adhesion molecules, and reactive oxygen species.","method":"siRNA silencing of MS4A6A in HUVECs with ox-LDL stimulation; IKK inhibitor (Bay 11-7085) and IKK siRNA; Western blot, ELISA, immunofluorescence; ApoE-/- mouse model with high-cholesterol diet","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with pharmacological and genetic pathway inhibition, in vitro and in vivo validation, single lab","pmids":["40090082"],"is_preprint":false},{"year":2017,"finding":"A SNP (rs667897) at the MS4A locus creates an antioxidant response element (ARE) that recruits CNC transcription factors NRF1 (NFE2L1) and NRF2 (NFE2L2); the risk allele generates a strong CNC binding sequence activated by proteostatic stress in an NRF1-dependent manner, driving increased MS4A6A expression.","method":"Reporter assays for ARE activity, transcription factor binding assays, luciferase/expression assays with NRF1/NRF2 manipulation under proteostatic stress conditions","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter assays with mutagenesis of the SNP site and NRF1-dependence established, single lab","pmids":["29179108"],"is_preprint":false},{"year":2019,"finding":"MS4A6A genetic variant rs7232 is associated with CSF soluble TREM2 (sTREM2) levels at genome-wide significance, and MS4A6A and TREM2 expression are correlated in brain regions, suggesting MS4A6A participates in the regulation of sTREM2.","method":"GWAS of CSF sTREM2 levels in ADNI cohort with validation in independent Chinese cohort; co-expression analysis in brain regions","journal":"Neurobiology of aging","confidence":"Low","confidence_rationale":"Tier 3 — genetic association with a molecular phenotype (sTREM2 levels), mechanistic link inferred but not directly tested","pmids":["31204042"],"is_preprint":false},{"year":2024,"finding":"MS4A6A is specifically expressed in microglial cells within glioblastoma tissue, and microglial overexpression of MS4A6A stimulates the proliferation and migration of glioblastoma cells in vitro.","method":"Single-cell RNA-sequencing database analysis, immunostaining for cell-type specificity; in vitro overexpression in microglia with glioblastoma cell proliferation/migration assay","journal":"The European journal of neuroscience","confidence":"Low","confidence_rationale":"Tier 3 — gain-of-function with phenotypic readout but no pathway placement, single lab","pmids":["38488530"],"is_preprint":false},{"year":2025,"finding":"MS4A6A knockdown in hiPSC-derived microglia increases reactive oxygen species production in response to poly(I:C) viral mimic, increases the proportion of cells in a poly(I:C)-driven inflammatory cluster, and reduces the proportion of microglia in the disease-associated microglia (DAM) cluster, indicating MS4A6A modulates the microglial DAM response.","method":"CRISPRi screens in hiPSC-derived microglia with ROS as functional readout; CROP-seq integrating CRISPRi with single-cell RNA sequencing","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPRi with single-cell transcriptomic readout linking MS4A6A KD to defined microglial state changes and inflammatory phenotype, preprint","pmids":[],"is_preprint":true}],"current_model":"MS4A6A is a tetraspan membrane protein expressed predominantly in microglia and mast cells that acts as a negative regulator of TREM2 signaling by forming a complex with DAP12 (blocking TREM2 surface localization and stability), is protected from degradation by its binding partner MS4A4A, promotes microglial phagocytosis of amyloid and suppresses NF-κB-driven neuroinflammation, and in mast cells compensates for FcεRIβ to traffic FcεRI to the cell surface and enable IgE-mediated degranulation."},"narrative":{"teleology":[{"year":2017,"claim":"Establishing how Alzheimer's-associated genetic variation at the MS4A locus controls MS4A6A expression: a risk SNP creates an antioxidant response element that recruits NRF1/NRF2 under proteostatic stress, providing a transcriptional mechanism linking GWAS signals to altered MS4A6A levels.","evidence":"Reporter assays with SNP site mutagenesis and NRF1/NRF2 manipulation under proteostatic stress","pmids":["29179108"],"confidence":"Medium","gaps":["Whether NRF1-driven upregulation occurs in microglia specifically, rather than heterologous cell lines","Whether increased MS4A6A expression from this allele alters microglial function in vivo"]},{"year":2019,"claim":"GWAS of CSF soluble TREM2 levels identified MS4A6A variant rs7232 as genome-wide significant, and co-expression analysis in brain linked MS4A6A to TREM2 regulation — providing the first molecular phenotype connecting MS4A6A to TREM2 biology, though without a direct mechanistic test.","evidence":"GWAS of CSF sTREM2 in ADNI cohort with replication in independent Chinese cohort; brain co-expression analysis","pmids":["31204042"],"confidence":"Low","gaps":["Purely genetic association without direct biochemical validation of how MS4A6A controls sTREM2","Direction of causality not established","No cell-type-resolved mechanism"]},{"year":2022,"claim":"Demonstrating a non-CNS function: MS4A6A traffics FcεRI complexes to the mast cell surface and enables IgE-mediated degranulation, acting as a compensatory FcεRIβ-like protein — establishing MS4A6A as a receptor trafficking chaperone in innate immunity.","evidence":"Exon-skipping oligonucleotides targeting FcεRIβ combined with degranulation assays in human mast cells","pmids":["36424895"],"confidence":"Medium","gaps":["Whether MS4A6A directly binds FcεRIα or acts indirectly through lipid raft organization","Not tested whether this function extends to other MS4A family members"]},{"year":2024,"claim":"Identifying MS4A6A as a microglial-specific factor in the glioblastoma microenvironment whose overexpression promotes tumor cell proliferation and migration — extending its functional repertoire to tumor-associated microglia.","evidence":"scRNA-seq localization to microglia in glioblastoma tissue; in vitro overexpression with tumor cell proliferation/migration assays","pmids":["38488530"],"confidence":"Low","gaps":["No pathway or receptor target identified for the pro-tumorigenic effect","Gain-of-function only, no loss-of-function validation","In vivo tumor model not tested"]},{"year":2025,"claim":"Resolving the biochemical mechanism by which MS4A6A controls TREM2: MS4A6A forms a complex with DAP12 that blocks TREM2 surface expression and signaling, while MS4A4A stabilizes MS4A6A protein, creating a druggable axis — antibody-mediated degradation of MS4A4A destabilizes MS4A6A and boosts TREM2.","evidence":"Reciprocal co-immunoprecipitation, CRISPR KO, MS4A4A-degrading antibodies in primary human microglia, non-human primates, and APP/PS1 amyloid mouse model","pmids":["41435829"],"confidence":"High","gaps":["Structural basis for MS4A6A–DAP12 interaction not resolved","Whether MS4A6A also sequesters other ITAM-bearing adaptors beyond DAP12"]},{"year":2025,"claim":"Demonstrating in vivo consequences: MS4A6A deficiency in amyloid mice impairs microglial plaque phagocytosis and decompacts plaques while disinhibiting NF-κB, establishing MS4A6A as a dual-function regulator that promotes phagocytosis yet restrains neuroinflammation.","evidence":"Ms4a6d-knockout APP/PS1 mice with high-resolution imaging, behavioral analysis, and transcriptomic validation via overexpression in human microglia","pmids":["40877951"],"confidence":"High","gaps":["Paradox between MS4A6A restraining TREM2 signaling via DAP12 yet being required for phagocytosis is not fully reconciled","Whether NF-κB disinhibition is a direct consequence of lost MS4A6A or secondary to altered TREM2/DAP12 dynamics"]},{"year":2025,"claim":"MS4A6A activates IKK/NF-κB signaling in ox-LDL-stimulated endothelial cells to drive inflammatory cytokine release and monocyte adhesion, extending its NF-κB regulatory role beyond microglia to vascular inflammation.","evidence":"siRNA knockdown in HUVECs with IKK inhibitor and IKK siRNA rescue; ApoE-knockout mouse model with high-cholesterol diet","pmids":["40090082"],"confidence":"Medium","gaps":["Direction of NF-κB regulation is opposite to microglia (activating here vs. suppressive in microglia), with no reconciliation","Direct molecular target linking MS4A6A to IKK activation not identified"]},{"year":2025,"claim":"CRISPRi knockdown in hiPSC-derived microglia showed MS4A6A loss increases ROS production and shifts microglia away from the disease-associated microglia (DAM) state toward an inflammatory state upon viral mimic stimulation — providing functional genomics confirmation that MS4A6A shapes microglial state transitions. (preprint)","evidence":"CRISPRi screens with ROS readout and CROP-seq single-cell transcriptomics in hiPSC-microglia (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Whether the DAM-promoting role of MS4A6A is TREM2/DAP12-dependent or operates through an independent pathway"]},{"year":null,"claim":"The apparent context-dependent directionality of MS4A6A's NF-κB regulation — suppressive in microglia but activating in endothelial cells — and whether its dual roles as a DAP12 sequesterer and phagocytosis promoter operate through the same or distinct molecular mechanisms remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural data for MS4A6A or its complexes with DAP12 or MS4A4A","Cell-type-specific signaling partners that explain opposing NF-κB phenotypes are unknown","Whether MS4A6A modulates additional ITAM-bearing adaptors beyond DAP12 has not been tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[0,1]}],"complexes":["MS4A6A–DAP12 complex","MS4A6A–MS4A4A complex"],"partners":["TYROBP","MS4A4A","TREM2"],"other_free_text":[]},"mechanistic_narrative":"MS4A6A is a tetraspan membrane protein expressed predominantly in microglia and mast cells that modulates innate immune receptor trafficking and inflammatory signaling. In microglia, MS4A6A forms a complex with the co-receptor DAP12 to restrain TREM2 surface localization and signaling, with its own stability maintained through interaction with MS4A4A [PMID:41435829]; loss of MS4A6A impairs microglial phagocytosis of amyloid plaques and disinhibits NF-κB signaling, exacerbating neuroinflammation and plaque pathology [PMID:40877951]. In human mast cells, MS4A6A compensates for FcεRIβ by trafficking the FcεRI receptor complex to the cell surface to enable IgE-mediated degranulation [PMID:36424895]. In endothelial cells, MS4A6A activates the IKK/NF-κB pathway to promote inflammatory cytokine production, adhesion molecule expression, and monocyte adhesion [PMID:40090082]."},"prefetch_data":{"uniprot":{"accession":"Q9H2W1","full_name":"Membrane-spanning 4-domains subfamily A member 6A","aliases":["CD20 antigen-like 3","Four-span transmembrane protein 3"],"length_aa":248,"mass_kda":26.9,"function":"May be involved in signal transduction as a component of a multimeric receptor complex","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q9H2W1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MS4A6A","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MS4A6A","total_profiled":1310},"omim":[{"mim_id":"608907","title":"ALZHEIMER DISEASE 9, SUSCEPTIBILITY TO; AD9","url":"https://www.omim.org/entry/608907"},{"mim_id":"608402","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6E; MS4A6E","url":"https://www.omim.org/entry/608402"},{"mim_id":"608401","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4E; MS4A4E","url":"https://www.omim.org/entry/608401"},{"mim_id":"606548","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6A; MS4A6A","url":"https://www.omim.org/entry/606548"},{"mim_id":"605414","title":"ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 7; ABCA7","url":"https://www.omim.org/entry/605414"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MS4A6A"},"hgnc":{"alias_symbol":["CD20L3"],"prev_symbol":["MS4A6"]},"alphafold":{"accession":"Q9H2W1","domains":[{"cath_id":"1.20.120","chopping":"39-153_175-212","consensus_level":"high","plddt":89.2024,"start":39,"end":212}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H2W1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H2W1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H2W1-F1-predicted_aligned_error_v6.png","plddt_mean":74.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MS4A6A","jax_strain_url":"https://www.jax.org/strain/search?query=MS4A6A"},"sequence":{"accession":"Q9H2W1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H2W1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H2W1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H2W1"}},"corpus_meta":[{"pmid":"21460840","id":"PMC_21460840","title":"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21460840","citation_count":1626,"is_preprint":false},{"pmid":"26923404","id":"PMC_26923404","title":"Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy.","date":"2015","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/26923404","citation_count":45,"is_preprint":false},{"pmid":"22382309","id":"PMC_22382309","title":"The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease.","date":"2012","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22382309","citation_count":45,"is_preprint":false},{"pmid":"24064185","id":"PMC_24064185","title":"Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24064185","citation_count":44,"is_preprint":false},{"pmid":"31204042","id":"PMC_31204042","title":"Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.","date":"2019","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/31204042","citation_count":35,"is_preprint":false},{"pmid":"29179108","id":"PMC_29179108","title":"A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease.","date":"2017","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/29179108","citation_count":25,"is_preprint":false},{"pmid":"27085534","id":"PMC_27085534","title":"The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27085534","citation_count":18,"is_preprint":false},{"pmid":"31799158","id":"PMC_31799158","title":"Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease.","date":"2019","source":"BioImpacts : BI","url":"https://pubmed.ncbi.nlm.nih.gov/31799158","citation_count":10,"is_preprint":false},{"pmid":"27337227","id":"PMC_27337227","title":"APOE and MS4A6A interact with GnRH signaling in Alzheimer's disease: Enrichment of epistatic effects.","date":"2016","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/27337227","citation_count":9,"is_preprint":false},{"pmid":"36424895","id":"PMC_36424895","title":"Identification of redundancy between human FcεRIβ and MS4A6A proteins points toward additional complex mechanisms for FcεRI trafficking and signaling.","date":"2022","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/36424895","citation_count":8,"is_preprint":false},{"pmid":"40090082","id":"PMC_40090082","title":"MS4A6A regulates ox-LDL-induced endothelial dysfunction and monocyte adhesion in atherosclerosis via the IKK/NF-kappaB pathway.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40090082","citation_count":5,"is_preprint":false},{"pmid":"38488530","id":"PMC_38488530","title":"Involvement of microglia-expressed MS4A6A in the onset of glioblastoma.","date":"2024","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38488530","citation_count":4,"is_preprint":false},{"pmid":"41435829","id":"PMC_41435829","title":"The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively regulate TREM2 and microglia states.","date":"2025","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/41435829","citation_count":2,"is_preprint":false},{"pmid":"38644829","id":"PMC_38644829","title":"Identifying MS4A6A+ macrophages as potential contributors to the pathogenesis of nonalcoholic fatty liver disease, periodontitis, and type 2 diabetes mellitus.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38644829","citation_count":2,"is_preprint":false},{"pmid":"40877951","id":"PMC_40877951","title":"MS4A6A/Ms4a6d deficiency disrupts neuroprotective microglia functions and promotes inflammation in Alzheimer's disease model.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/40877951","citation_count":2,"is_preprint":false},{"pmid":"41552371","id":"PMC_41552371","title":"Plasma TREM2 levels, alcohol consumption, and liver enzymes in patients with alcohol use disorder: a sex-dependent relationship involving MS4A6A genetic polymorphism.","date":"2025","source":"Journal of proteomics and genomics research","url":"https://pubmed.ncbi.nlm.nih.gov/41552371","citation_count":1,"is_preprint":false},{"pmid":"41515934","id":"PMC_41515934","title":"The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41515934","citation_count":0,"is_preprint":false},{"pmid":"41694841","id":"PMC_41694841","title":"Transient Neonatal Diabetes Mellitus Potentially Associated With a Novel Homozygous MS4A6A Gene Variant: A Case Report.","date":"2026","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/41694841","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.09.642133","title":"High throughput identification of genetic regulators of microglial inflammatory processes in Alzheimer’s disease","date":"2025-03-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.09.642133","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.23.625001","title":"The Alzheimer’s Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states","date":"2024-11-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.23.625001","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.24.24316008","title":"Complex genetic interactions affect susceptibility to Alzheimer's disease risk in the BIN1 and MS4A6A loci","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.24.24316008","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.07.25325386","title":"Silencer variants are key drivers of gene upregulation in Alzheimer’s disease","date":"2025-04-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.07.25325386","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13114,"output_tokens":2096,"usd":0.035391},"stage2":{"model":"claude-opus-4-6","input_tokens":5419,"output_tokens":2572,"usd":0.137093},"total_usd":0.172484,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"MS4A6A promotes surface expression of FcεRI complexes on human mast cells and facilitates IgE-mediated degranulation, functioning as a compensatory FcεRIβ-like protein that traffics the FcεRI receptor complex to the cell surface.\",\n      \"method\": \"Exon-skipping oligonucleotides targeting FcεRIβ combined with functional degranulation assays in human mast cells; loss-of-function and compensation experiments\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined cellular phenotype (degranulation), mechanistic link to FcεRI trafficking established, single lab\",\n      \"pmids\": [\"36424895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A6A forms a complex with and blocks the co-receptor DAP12, which modulates the levels, cell surface localization, and signaling of TREM2 and other receptors. MS4A4A interacts with MS4A6A and protects it from degradation, thereby indirectly restraining TREM2 signaling.\",\n      \"method\": \"Co-immunoprecipitation, CRISPR knockout, MS4A4A-degrading antibodies in primary human microglia, non-human primates, and amyloid mouse model; western blot for TREM2 protein levels\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP for complex identification, CRISPR KO, antibody-mediated degradation, and multiple orthogonal model systems (human cells, NHP, mouse); replicated across preprint and peer-reviewed publication\",\n      \"pmids\": [\"41435829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A6A deficiency (Ms4a6d knockout in APP/PS1 mice) impairs microglial phagocytosis and envelopment of amyloid plaques, leading to increased plaque burden, less compact plaque structure, and more severe synaptic damage; mechanistically, Ms4a6d deficiency disinhibits NF-κB signaling, exacerbating inflammation in microglia and astrocytes.\",\n      \"method\": \"Ms4a6d-deficient APP/PS1 mouse model, high-resolution microscopy, biochemistry, behavioral analysis, immunostaining; overexpression in human microglia cell line with transcriptomic readout\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotypes (phagocytosis, NF-κB pathway), orthogonal overexpression experiment, in vivo model\",\n      \"pmids\": [\"40877951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A6A promotes endothelial dysfunction and monocyte adhesion in ox-LDL-stimulated human umbilical vein endothelial cells by activating the IKK/NF-κB signaling pathway; silencing MS4A6A reduced inflammatory cytokines, adhesion molecules, and reactive oxygen species.\",\n      \"method\": \"siRNA silencing of MS4A6A in HUVECs with ox-LDL stimulation; IKK inhibitor (Bay 11-7085) and IKK siRNA; Western blot, ELISA, immunofluorescence; ApoE-/- mouse model with high-cholesterol diet\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with pharmacological and genetic pathway inhibition, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"40090082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A SNP (rs667897) at the MS4A locus creates an antioxidant response element (ARE) that recruits CNC transcription factors NRF1 (NFE2L1) and NRF2 (NFE2L2); the risk allele generates a strong CNC binding sequence activated by proteostatic stress in an NRF1-dependent manner, driving increased MS4A6A expression.\",\n      \"method\": \"Reporter assays for ARE activity, transcription factor binding assays, luciferase/expression assays with NRF1/NRF2 manipulation under proteostatic stress conditions\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter assays with mutagenesis of the SNP site and NRF1-dependence established, single lab\",\n      \"pmids\": [\"29179108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MS4A6A genetic variant rs7232 is associated with CSF soluble TREM2 (sTREM2) levels at genome-wide significance, and MS4A6A and TREM2 expression are correlated in brain regions, suggesting MS4A6A participates in the regulation of sTREM2.\",\n      \"method\": \"GWAS of CSF sTREM2 levels in ADNI cohort with validation in independent Chinese cohort; co-expression analysis in brain regions\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — genetic association with a molecular phenotype (sTREM2 levels), mechanistic link inferred but not directly tested\",\n      \"pmids\": [\"31204042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MS4A6A is specifically expressed in microglial cells within glioblastoma tissue, and microglial overexpression of MS4A6A stimulates the proliferation and migration of glioblastoma cells in vitro.\",\n      \"method\": \"Single-cell RNA-sequencing database analysis, immunostaining for cell-type specificity; in vitro overexpression in microglia with glioblastoma cell proliferation/migration assay\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — gain-of-function with phenotypic readout but no pathway placement, single lab\",\n      \"pmids\": [\"38488530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MS4A6A knockdown in hiPSC-derived microglia increases reactive oxygen species production in response to poly(I:C) viral mimic, increases the proportion of cells in a poly(I:C)-driven inflammatory cluster, and reduces the proportion of microglia in the disease-associated microglia (DAM) cluster, indicating MS4A6A modulates the microglial DAM response.\",\n      \"method\": \"CRISPRi screens in hiPSC-derived microglia with ROS as functional readout; CROP-seq integrating CRISPRi with single-cell RNA sequencing\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPRi with single-cell transcriptomic readout linking MS4A6A KD to defined microglial state changes and inflammatory phenotype, preprint\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"MS4A6A is a tetraspan membrane protein expressed predominantly in microglia and mast cells that acts as a negative regulator of TREM2 signaling by forming a complex with DAP12 (blocking TREM2 surface localization and stability), is protected from degradation by its binding partner MS4A4A, promotes microglial phagocytosis of amyloid and suppresses NF-κB-driven neuroinflammation, and in mast cells compensates for FcεRIβ to traffic FcεRI to the cell surface and enable IgE-mediated degranulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MS4A6A is a tetraspan membrane protein expressed predominantly in microglia and mast cells that modulates innate immune receptor trafficking and inflammatory signaling. In microglia, MS4A6A forms a complex with the co-receptor DAP12 to restrain TREM2 surface localization and signaling, with its own stability maintained through interaction with MS4A4A [PMID:41435829]; loss of MS4A6A impairs microglial phagocytosis of amyloid plaques and disinhibits NF-κB signaling, exacerbating neuroinflammation and plaque pathology [PMID:40877951]. In human mast cells, MS4A6A compensates for FcεRIβ by trafficking the FcεRI receptor complex to the cell surface to enable IgE-mediated degranulation [PMID:36424895]. In endothelial cells, MS4A6A activates the IKK/NF-κB pathway to promote inflammatory cytokine production, adhesion molecule expression, and monocyte adhesion [PMID:40090082].\",\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing how Alzheimer's-associated genetic variation at the MS4A locus controls MS4A6A expression: a risk SNP creates an antioxidant response element that recruits NRF1/NRF2 under proteostatic stress, providing a transcriptional mechanism linking GWAS signals to altered MS4A6A levels.\",\n      \"evidence\": \"Reporter assays with SNP site mutagenesis and NRF1/NRF2 manipulation under proteostatic stress\",\n      \"pmids\": [\"29179108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether NRF1-driven upregulation occurs in microglia specifically, rather than heterologous cell lines\",\n        \"Whether increased MS4A6A expression from this allele alters microglial function in vivo\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"GWAS of CSF soluble TREM2 levels identified MS4A6A variant rs7232 as genome-wide significant, and co-expression analysis in brain linked MS4A6A to TREM2 regulation — providing the first molecular phenotype connecting MS4A6A to TREM2 biology, though without a direct mechanistic test.\",\n      \"evidence\": \"GWAS of CSF sTREM2 in ADNI cohort with replication in independent Chinese cohort; brain co-expression analysis\",\n      \"pmids\": [\"31204042\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Purely genetic association without direct biochemical validation of how MS4A6A controls sTREM2\",\n        \"Direction of causality not established\",\n        \"No cell-type-resolved mechanism\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating a non-CNS function: MS4A6A traffics FcεRI complexes to the mast cell surface and enables IgE-mediated degranulation, acting as a compensatory FcεRIβ-like protein — establishing MS4A6A as a receptor trafficking chaperone in innate immunity.\",\n      \"evidence\": \"Exon-skipping oligonucleotides targeting FcεRIβ combined with degranulation assays in human mast cells\",\n      \"pmids\": [\"36424895\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether MS4A6A directly binds FcεRIα or acts indirectly through lipid raft organization\",\n        \"Not tested whether this function extends to other MS4A family members\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying MS4A6A as a microglial-specific factor in the glioblastoma microenvironment whose overexpression promotes tumor cell proliferation and migration — extending its functional repertoire to tumor-associated microglia.\",\n      \"evidence\": \"scRNA-seq localization to microglia in glioblastoma tissue; in vitro overexpression with tumor cell proliferation/migration assays\",\n      \"pmids\": [\"38488530\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No pathway or receptor target identified for the pro-tumorigenic effect\",\n        \"Gain-of-function only, no loss-of-function validation\",\n        \"In vivo tumor model not tested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolving the biochemical mechanism by which MS4A6A controls TREM2: MS4A6A forms a complex with DAP12 that blocks TREM2 surface expression and signaling, while MS4A4A stabilizes MS4A6A protein, creating a druggable axis — antibody-mediated degradation of MS4A4A destabilizes MS4A6A and boosts TREM2.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, CRISPR KO, MS4A4A-degrading antibodies in primary human microglia, non-human primates, and APP/PS1 amyloid mouse model\",\n      \"pmids\": [\"41435829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for MS4A6A–DAP12 interaction not resolved\",\n        \"Whether MS4A6A also sequesters other ITAM-bearing adaptors beyond DAP12\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating in vivo consequences: MS4A6A deficiency in amyloid mice impairs microglial plaque phagocytosis and decompacts plaques while disinhibiting NF-κB, establishing MS4A6A as a dual-function regulator that promotes phagocytosis yet restrains neuroinflammation.\",\n      \"evidence\": \"Ms4a6d-knockout APP/PS1 mice with high-resolution imaging, behavioral analysis, and transcriptomic validation via overexpression in human microglia\",\n      \"pmids\": [\"40877951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Paradox between MS4A6A restraining TREM2 signaling via DAP12 yet being required for phagocytosis is not fully reconciled\",\n        \"Whether NF-κB disinhibition is a direct consequence of lost MS4A6A or secondary to altered TREM2/DAP12 dynamics\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"MS4A6A activates IKK/NF-κB signaling in ox-LDL-stimulated endothelial cells to drive inflammatory cytokine release and monocyte adhesion, extending its NF-κB regulatory role beyond microglia to vascular inflammation.\",\n      \"evidence\": \"siRNA knockdown in HUVECs with IKK inhibitor and IKK siRNA rescue; ApoE-knockout mouse model with high-cholesterol diet\",\n      \"pmids\": [\"40090082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direction of NF-κB regulation is opposite to microglia (activating here vs. suppressive in microglia), with no reconciliation\",\n        \"Direct molecular target linking MS4A6A to IKK activation not identified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"CRISPRi knockdown in hiPSC-derived microglia showed MS4A6A loss increases ROS production and shifts microglia away from the disease-associated microglia (DAM) state toward an inflammatory state upon viral mimic stimulation — providing functional genomics confirmation that MS4A6A shapes microglial state transitions. (preprint)\",\n      \"evidence\": \"CRISPRi screens with ROS readout and CROP-seq single-cell transcriptomics in hiPSC-microglia (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Preprint not yet peer-reviewed\",\n        \"Whether the DAM-promoting role of MS4A6A is TREM2/DAP12-dependent or operates through an independent pathway\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The apparent context-dependent directionality of MS4A6A's NF-κB regulation — suppressive in microglia but activating in endothelial cells — and whether its dual roles as a DAP12 sequesterer and phagocytosis promoter operate through the same or distinct molecular mechanisms remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural data for MS4A6A or its complexes with DAP12 or MS4A4A\",\n        \"Cell-type-specific signaling partners that explain opposing NF-κB phenotypes are unknown\",\n        \"Whether MS4A6A modulates additional ITAM-bearing adaptors beyond DAP12 has not been tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0002376\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [\n      \"MS4A6A–DAP12 complex\",\n      \"MS4A6A–MS4A4A complex\"\n    ],\n    \"partners\": [\n      \"TYROBP\",\n      \"MS4A4A\",\n      \"TREM2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}